Santos M J, Conde M, Mourão A F, Ramos F O, Cabral M, Brito I, Ramos M P, Marques R C, Gomes S M, Guedes M, Gonçalves M J, Estanqueiro P, Zilhão C, Rodrigues M, Henriques C, Salgado M, Canhão H, Fonseca J E, Gomes J M
Acta Reumatol Port. 2016 Jul-Sep;41(3):194-212.
To provide evidence-based guidance for the rational and safe prescription of biological therapies in children and adolescents with juvenile idiopathic arthritis (JIAs) considering the latest available evidence and the new licensed biologics.
Rheumatologists and Pediatricians with expertise in Pediatric Rheumatology updated the recommendations endorsed by the Portuguese Society of Rheumatology and the Portuguese Society of Pediatrics based on published evidence and expert opinion. The level of agreement with final propositions was voted using an online survey.
In total, 20 recommendations to guide the use of biological therapy in children and adolescents with JIAs are issued, comprising 4 general principles and 16 specific recommendations. A consensus was achieved regarding the eligibility and response criteria, maintenance of biological therapy, and procedures in case of non-response, for each JIA category. Specific recommendations concerning safety procedures were also updated.
These recommendations take into account the specificities of each JIA category and are intended to continuously improve the management of JIA patients.
考虑到最新可得证据和新获批的生物制剂，为青少年特发性关节炎（JIA）患儿及青少年合理、安全地开具生物疗法处方提供循证指导。
具有儿科风湿病专业知识的风湿病学家和儿科医生根据已发表的证据和专家意见，更新了葡萄牙风湿病学会和葡萄牙儿科学会认可的建议。通过在线调查对最终提议的认同程度进行投票。
共发布了20条指导JIA患儿及青少年生物疗法使用的建议，包括4条一般原则和16条具体建议。就每种JIA类型的资格和反应标准、生物疗法的维持以及无反应情况下的程序达成了共识。关于安全程序的具体建议也进行了更新。
这些建议考虑了每种JIA类型的特殊性，旨在持续改善JIA患者的管理。
